Predictive factors of hospitalizations in Alzheimer’s disease: A two-year prospective study in 686 patients of the REAL.FR study

2010 ◽  
Vol 14 (4) ◽  
pp. 288-291 ◽  
Author(s):  
T. Voisin ◽  
◽  
S. Andrieu ◽  
C. Cantet ◽  
B. Vellas
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Prospective Study ◽  
Predictive Factors

Predictive factors of acute hospitalization in 134 patients with Alzheimer's disease: a one year prospective study

2002 ◽  
Vol 17 (5) ◽  
pp. 422-426 ◽  
Author(s):  
Sandrine Andrieu ◽  
Emma Reynish ◽  
Fati Nourhashemi ◽  
Annabelle Shakespeare ◽  
Sophie Moulias ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Prospective Study ◽  
Predictive Factors ◽  
Acute Hospitalization ◽  
One Year

Prognosis of Alzheimer's disease today: A two-year prospective study in 686 patients from the REAL-FR Study

2008 ◽  
Vol 4 (1) ◽  
pp. 22-29 ◽  
Author(s):  
Frédéric Cortes ◽  
Fati Nourhashémi ◽  
Olivier Guérin ◽  
Christelle Cantet ◽  
Sophie Gillette-Guyonnet ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Prospective Study ◽  
The Real

362-S: Prospective Study of Diabetes, Gender, and Subsequent Risk of Alzheimer's Disease: The Cache County Study on Memory, Health, and Aging

2005 ◽  
Vol 161 (Supplement_1) ◽  
pp. S91-S91 ◽  
Author(s):  
G Charoonruk ◽  
R Munger ◽  
H Wengreen ◽  
C Corcoran ◽  
K Hayden ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Prospective Study ◽  
Cache County ◽  
Subsequent Risk

scholarly journals Anesthesia Exposure and Risk of Dementia and Alzheimer's Disease: A Prospective Study

2016 ◽  
Vol 64 (3) ◽  
pp. 602-607 ◽  
Author(s):  
Erin J. Aiello Bowles ◽  
Eric B. Larson ◽  
Ryan P. Pong ◽  
Rod L. Walker ◽  
Melissa L. Anderson ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Prospective Study ◽  
A Prospective Study

Cognitive function and caregiver burden: predictive factors for eating behaviour disorders in Alzheimer's disease

2002 ◽  
Vol 17 (10) ◽  
pp. 950-955 ◽  
Author(s):  
Stéphanie Rivière ◽  
Sophie Gillette-Guyonnet ◽  
Sandrine Andrieu ◽  
Fati Nourhashemi ◽  
Sylvie Lauque ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Function ◽  
Caregiver Burden ◽  
Predictive Factors ◽  
Eating Behaviour

scholarly journals Plasma Glutathione Levels Decreased with Cognitive Decline among People with Mild Cognitive Impairment (MCI): A Two-Year Prospective Study

Antioxidants ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. 1839
Author(s):  
Chieh-Hsin Lin ◽  
Hsien-Yuan Lane
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Cognitive Function ◽  
Prospective Study ◽  
Cognitive Decline ◽  
Cognitive Change ◽  
Disease Assessment ◽  
Healthy Individuals

Glutathione (GSH) is a major endogenous antioxidant. Several studies have shown GSH redox imbalance and altered GSH levels in Alzheimer’s disease (AD) patients. Early detection is crucial for the outcome of AD. However, whether GSH can serve as a biomarker during the very early-phase of AD, such as mild cognitive impairment (MCI), remains unknown. The current prospective study aimed to examine the longitudinal change in plasma GSH concentration and its influence on cognitive decline in MCI. Overall, 49 patients with MCI and 16 healthy individuals were recruited. Plasma GSH levels and cognitive function, measured by the Mini-Mental Status Examination (MMSE) and Alzheimer’s disease assessment scale-cognitive subscale (ADAS-cog), were monitored every 6 months. We employed multiple regressions to examine the role of GSH level in cognitive decline in the 2 years period. The MCI patients showed significant decline in plasma GSH levels and cognitive function from baseline to endpoint (month 24). In comparison, the healthy individuals’ GSH concentration and cognitive function did not change significantly. Further, both GSH level at baseline and GSH level change from baseline to endpoint significantly influenced cognitive decline among the MCI patients. To our knowledge, this is the first study to demonstrate that both plasma GSH levels and cognitive function declined 2 years later among the MCI patients in a prospective manner. If replicated by future studies, blood GSH concentration may be regarded as a biomarker for monitoring cognitive change in MCI.

Sign in / Sign up

Export Citation Format

Share Document